Out of 11 CML and 10 Ph+ ALL patients with mutations in the BCR-ABL1 kinase domain, 6 (55%) CML and 6 (60%) Ph+ ALL patients had the T315I mutation. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.